Cancer Drugs Cost Way Less to Develop Than What We've Been Led to Think, Study Claims
It's no secret that developing and clinically testing drugs to treat conditions like cancer is a long and rigorous process. But the financial costs could be dramatically less than many people think. An oft-quoted figure used by the pharmaceutical industry and once even referenced by President Trump puts the outlay at about US$2.7 billion in 2017 dollars to bring a drug to market, but a new analysis suggests that's way more than what it actually costs.
No comments:
Post a Comment